Trial Profile
A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 13 Jul 2015 Results published in the Journal of Antimicrobial Chemotherapy.
- 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 28 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.